Acute Lymphoblastic Leukemia


Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings (12-31-2015)

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH)... Continue Reading

Addition of Rituxan Improves Outcomes in Some Acute Lymphoblastic Leukemias (12-16-2015)

The addition of Rituxan (rituximab) to standard chemotherapy-based regimens improves outcomes among patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) that is CD20-positive. These results were reported at a plenary session at the 2015... Continue Reading

Blincyto® in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Appears Promising (07-23-2015)

Biotechnology company Amgen has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings... Continue Reading

Blincyto® (05-19-2015)

Class: Biological Therapy Generic Name: blinatumomab Trade Name: Blincyto® For which conditions is this drug approved? Blincyto® is approved for treatment of a certain type of acute lymphoblastic leukemia (ALL): Philadelphia chromosome-negative relapsed... Continue Reading

blinatumomab (05-19-2015)

Class: Biological Therapy Generic Name: blinatumomab Trade Name: Blincyto® For which conditions is this drug approved? Blincyto® is approved for treatment of a certain type of acute lymphoblastic leukemia (ALL): Philadelphia chromosome-negative relapsed... Continue Reading

Intravenous Administration of Erwinaze® Approved by FDA (02-18-2015)

The U.S. Food and Drug Administration (FDA) recently approved the intravenous administration of Erwinaze® (asparaginase Erwinia chrysanthemi).  Erwinaze is utilized as a component of a multi-agent chemotherapeutic regimen for the treatment of patients... Continue Reading

FDA Approves Blinatumomab for Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia (01-12-2015)

On December 3, 2014, the U. S. Food and Drug Administration granted accelerated approval for BLINCYTOTM (blinatumomab) for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Acute... Continue Reading

CD19-Directed CAR T Cells Effective in Management of Relapsed/Refractory Acute Lymphoblastic Leukemia (10-27-2014)

In a study recently published in The New England Journal of Medicine, doctors have reported achieving sustained remissions in children and adults with relapsed/refractory acute lymphoblastic leukemia (ALL) using CD19-targeted chimeric antigen receptor... Continue Reading

Amgen’s BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia (10-10-2014)

THOUSAND OAKS, Calif., Oct. 9, 2014 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell... Continue Reading

Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment (07-21-2014)

A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment, which involves extracting specific white blood... Continue Reading

« Previous PageNext Page »